COVID-19: Vaccines and Therapeutics

The Centers for Medicare & Medicaid Services recently posted information on how hospitals and other health care providers should bill Medicare for administering COVID-19 vaccines.
The Department of Health and Human Services Dec. 11 announced it would purchase from Moderna 100 million additional doses of its mRNA-1273 COVID-19 vaccine candidate.
Following the Food and Drug Administration’s Dec. 11 emergency use authorization of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine, AHA released a Special Bulletin with important details for hospitals and health systems.
The Food and Drug Administration late last night granted an emergency use authorization (EUA) to Pfizer, Inc. for its BNT162b2 mRNA COVID-19 vaccine, paving the way for its immediate administration across the country. Health care workers and nursing home residents will receive first priority and…
The Food and Drug Administration today granted an emergency use authorization to Pfizer, Inc. for its BNT162b2 mRNA COVID-19 vaccine, paving the way for its immediate administration across the country. The vaccine is administered in two doses, 21 days apart, and requires ultracold (minus-70 degrees…
AHA statement on FDA Emergency Use Authorization of Pfizer COVID-19 Vaccine from President and CEO Rick Pollack.
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Dec. 10 recommended the approval of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine. The panel voted 17-4, with one abstention, that FDA issue an emergency use authorization.
The Department of Defense announced a phased plan for the distribution and administration of initial and subsequent COVID-19 vaccine allocations to populations of DoD uniformed service members, including members of the National Guard; dependents; retirees; civilian employees; and select DoD…
Peer-reviewed data for Pfizer Inc.’s BNT162b2 mRNA COVID-19 vaccine candidate was published by the New England Journal of Medicine, confirming its safety and efficacy.